287 related articles for article (PubMed ID: 17094481)
1. HSP-70, C-myc and HLA-DR expression in patients with cutaneous malignant melanoma metastatic in lymph nodes.
Kalogeraki A; Garbagnati F; Darivianaki K; Delides GS; Santinami M; Stathopoulos EN; Zoras O
Anticancer Res; 2006; 26(5A):3551-4. PubMed ID: 17094481
[TBL] [Abstract][Full Text] [Related]
2. Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanoma.
Ricaniadis N; Kataki A; Agnantis N; Androulakis G; Karakousis CP
Eur J Surg Oncol; 2001 Feb; 27(1):88-93. PubMed ID: 11237497
[TBL] [Abstract][Full Text] [Related]
3. Molecular oncogene markers and their significance in cutaneous malignant melanoma.
Konstadoulakis MM; Vezeridis M; Hatziyianni E; Karakousis CP; Cole B; Bland KI; Wanebo HJ
Ann Surg Oncol; 1998; 5(3):253-60. PubMed ID: 9607628
[TBL] [Abstract][Full Text] [Related]
4. Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis.
Martins I; Sylla K; Deshayes F; Lauriol J; Ghislin S; Dieu-Nosjean MC; Viguier M; Verola O; Charron D; Alcaide-Loridan C; Al-Daccak R
Melanoma Res; 2009 Aug; 19(4):226-37. PubMed ID: 19574933
[TBL] [Abstract][Full Text] [Related]
5. Lymphangiogenesis and its relationship with lymphatic metastasis and prognosis in malignant melanoma.
Liu B; Ma J; Wang X; Su F; Li X; Yang S; Ma W; Zhang Y
Anat Rec (Hoboken); 2008 Oct; 291(10):1227-35. PubMed ID: 18561194
[TBL] [Abstract][Full Text] [Related]
6. Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi.
Holt JB; Sangueza OP; Levine EA; Shen P; Bergman S; Geisinger KR; Creager AJ
Am J Clin Pathol; 2004 Jan; 121(1):58-63. PubMed ID: 14750241
[TBL] [Abstract][Full Text] [Related]
7. Strong HLA-DR antigen expression on cancer cells relates to better prognosis of colorectal cancer patients: Possible involvement of c-myc suppression by interferon-gamma in situ.
Matsushita K; Takenouchi T; Shimada H; Tomonaga T; Hayashi H; Shioya A; Komatsu A; Matsubara H; Ochiai T
Cancer Sci; 2006 Jan; 97(1):57-63. PubMed ID: 16367922
[TBL] [Abstract][Full Text] [Related]
8. The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma.
Thies A; Schachner M; Berger J; Moll I; Schulze HJ; Brunner G; Schumacher U
J Pathol; 2004 Aug; 203(4):933-9. PubMed ID: 15258996
[TBL] [Abstract][Full Text] [Related]
9. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma.
Grover R; Chana J; Grobbelaar AO; Hudson DA; Forder M; Wilson GD; Sanders R
Br J Plast Surg; 1999 Mar; 52(2):122-6. PubMed ID: 10434891
[TBL] [Abstract][Full Text] [Related]
10. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.
Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
Melanoma Res; 2007 Dec; 17(6):393-9. PubMed ID: 17992123
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of C-myc oncogene, heat shock protein 70 and HLA-DR molecules in malignant cutaneous melanoma.
Lazaris AC; Theodoropoulos GE; Aroni K; Saetta A; Davaris PS
Virchows Arch; 1995; 426(5):461-7. PubMed ID: 7633656
[TBL] [Abstract][Full Text] [Related]
12. Inverse correlation between expression of HLA-B and c-myc in uveal melanoma.
Blom DJ; Mooy CM; Luyten GP; Kerkvliet S; Ouwerkerk I; Zwinderman AH; Schrier PI; Jager MJ
J Pathol; 1997 Jan; 181(1):75-9. PubMed ID: 9072006
[TBL] [Abstract][Full Text] [Related]
13. Expression of c-myc oncoprotein represents a new prognostic marker in cutaneous melanoma.
Ross DA; Wilson GD
Br J Surg; 1998 Jan; 85(1):46-51. PubMed ID: 9462382
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypically varied cell subpopulations in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy.
Bodey B; Kaiser HE; Goldfarb RH
Anticancer Res; 1996; 16(1):517-31. PubMed ID: 8615665
[TBL] [Abstract][Full Text] [Related]
15. The clinical significance of c-myc oncogene expression in melanomas of the scalp.
Chana JS; Grover R; Wilson GD; Hudson DA; Forders M; Sanders R; Grobbelaar AO
Br J Plast Surg; 1998 Apr; 51(3):191-4. PubMed ID: 9664877
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
Nishizawa A; Nakanishi Y; Yoshimura K; Sasajima Y; Yamazaki N; Yamamoto A; Hanada K; Kanai Y; Hirohashi S
Cancer; 2005 Apr; 103(8):1693-700. PubMed ID: 15751018
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic and genetic analysis of HLA class I and HLA-DR antigen expression on human melanomas.
López-Nevot MA; Garcia E; Romero C; Oliva MR; Serrano S; Garrido F
Exp Clin Immunogenet; 1988; 5(4):203-12. PubMed ID: 3078572
[TBL] [Abstract][Full Text] [Related]
18. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of CD8, CD4, CD68, and human leukocyte antigen-D-related cells in the prognosis of cutaneous malignant melanoma with vertical growth phase.
Piras F; Colombari R; Minerba L; Murtas D; Floris C; Maxia C; Corbu A; Perra MT; Sirigu P
Cancer; 2005 Sep; 104(6):1246-54. PubMed ID: 16078259
[TBL] [Abstract][Full Text] [Related]
20. Expression of heat shock protein 105 and 70 in malignant melanoma and benign melanocytic nevi.
Park HS; Park CH; Choi BR; Lim MS; Heo SH; Kim CH; Kang SG; Whang KU; Cho MK
J Cutan Pathol; 2009 May; 36(5):511-6. PubMed ID: 19476517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
